Lung Cancer
Conference Coverage
Air pollution contribution to lung cancer may be underestimated
A study of women with lung cancer who never smoked suggests that air pollution may be a larger risk factor for lung cancer than currently...
Conference Coverage
Smoking cessation with lung screening ups quit rates
Offering smoking cessation support at the time and place of lung cancer screening resulted in high smoking abstinence rates at 1 year.
From the Journals
CV admissions on the rise in Americans with cancer
“I would say that this increase in cardiovascular admissions, that’s a failure from a preventative perspective.”
From the Journals
One in four NSCLC patients respond poorly to COVID-19 vaccine
The reasons are unclear, but point to the need for NSCLC patients to have titers checked.
From the Journals
Lung cancer treatment combo may be effective after ICI failure
Phase 2 trial offers hope of a chemotherapy-free option for patients with advanced NSCLC.
Conference Coverage
The shifting sands of lung cancer screening
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
From the Journals
New KRAS inhibitor shows promise in NSCLC
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
Commentary
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
From the Journals
Quality of life benefit exaggerated in some cancer studies
From the Journals
Cancer may increase risk of type 2 diabetes
Study demonstrates elevated risk of developing diabetes for people with lung, pancreatic, breast, brain, urinary tract, or uterine cancers
From the Journals
Good chemo vs. bad chemo: When too much is a bad thing
Study questions the use of inpatient chemotherapy pointing to negative outcomes and high mortality among some patients.